Double-Masked Study of Photrex (Rostaporfin) Photodynamic Therapy in the Treatment of Age-Related Macular Degeneration

A Phase III Randomized, Multicenter, Multinational, Double-Masked, Placebo-Controlled Study of Photrex (Rostaporfin) Photodynamic Therapy in the Treatment of Classic and Occult Subfoveal Choroidal Neovascularization Associated With AMD

Status

UNKNOWN

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00157976

Enrollment

660

Registered

2005-09-12

Start date

2005-09-30

Completion date

Unknown

Last updated

2005-12-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Macular Degeneration

Keywords

Macular Degeneration, AMD, Visual Acuity

Brief summary

The purpose of this study is to confirm the efficacy and safety of rostaporfin (PHOTREX) photodynamic therapy (PDT) in the treatment of classic and occult subfoveal choroidal neovascularization (CNV) associated with age-related macular degeneration (AMD).

Interventions

DRUGPhotrex (rostaporfin)

Study design

Allocation

RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

DOUBLE

Eligibility

Sex/Gender

ALL

Age

50 Years to No maximum

Healthy volunteers

Inclusion criteria

Patients with age greater than or equal to 50 years with at least one subfoveal CNV membrane secondary to AMD that can be demonstrated by fluorescein angiography.

Design outcomes

Primary

Measure	Time frame
Visual Acuity	—

Secondary

Measure	Time frame
Angiographic changes	—

Countries

Bulgaria, Czechia, Poland, Romania

Contacts

Primary ContactMiravant Pharmaceuticals

ctinfo@miravant.com1-800-685-2959

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026